Isoindoline Derivatives as D1 Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing orally-bioavailable small molecules that selectively target D1 receptors has been challenging due to the high degree of homology in the ligand binding site between dopamine receptor subtypes, leading to limited clinical use and adverse effects such as dyskinesia and hypotension, as well as the development of tolerance in animal models.
Innovation Solution
The development of isoindoline derivatives that act as D1 positive allosteric modulators, which potentiate the effect of dopamine on D1 receptors through an allosteric mechanism, providing a novel site for modulation to improve selectivity and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D1 agonists with catechol moiety are developed to target D1 receptors, then D1 receptor activation is achieved, but selectivity is reduced and adverse effects occur
Solution Approach 1:
The patent introduces an allosteric modulator as an intermediary compound that indirectly activates D1 receptors by binding to a distinct allosteric site rather than the orthosteric site. This mediator enhances the effect of endogenous dopamine while avoiding direct competition at the homology-prone orthosteric binding site, thereby maintaining selectivity and reducing adverse effects associated with traditional D1 agonists.
Solution Approach 2:
The patent transitions from orthosteric binding (one-dimensional competition at the natural ligand site) to allosteric binding (adding a new dimension by targeting a distinct regulatory site). This dimensional shift allows modulation of D1 receptor function through a different binding interface that exhibits less homology across dopamine receptor subtypes, improving selectivity while achieving the desired pharmacological effect.
2Reliability
If D1 agonists are used to treat diseases, then therapeutic effect is achieved, but tolerance develops in animal models
Solution Approach 1:
The allosteric modulator provides a more physiological pattern of receptor activation that mimics natural dopamine signaling more closely. By potentiating rather than directly activating receptors, the compound produces more modulated, less sustained activation patterns that resemble endogenous neurotransmission, thereby reducing the development of tolerance that occurs with continuous direct agonist stimulation.
Solution Approach 2:
The allosteric modulator requires the presence of endogenous dopamine to produce its full therapeutic effect, making the system self-regulating. The compound does not independently activate receptors but rather enhances the action of naturally released dopamine, creating a feedback-dependent activation pattern that prevents overstimulation and reduces tolerance development.
3Ease of manufacture
If small molecules are designed to target D1 receptors, then oral bioavailability is sought, but selectivity is compromised due to high homology in ligand binding site
Solution Approach 1:
The patent targets a specific local region (the allosteric site) that has distinct structural and functional properties compared to the orthosteric site. This localized targeting exploits the unique characteristics of the allosteric binding pocket, which shows greater divergence across dopamine receptor subtypes, thereby achieving selectivity while maintaining the small molecule format necessary for oral bioavailability.
Data Source
AI summary
The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.